Shopping Cart 0
Cart Subtotal
USD 0

Cempra Inc (CEMP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Cempra Inc (Cempra), formerly Cempra Holdings LLC is a pharmaceutical company that develops antibacterials to the critical medical needs. The company offers products which include solithromycin and fusidic acid. It offers solithromycin, an oral and intravenous fluoroketolide. Cempra offers fusidic acid which is active against gram-positive organisms including MRSA. The company offers macrolides which are antimicrobial drugs that are active against aerobic and anaerobic gram-positive cocci and are prescribed for the treatment of respiratory tract and soft tissue infection. It markets its products across the US. Cempra is headquartered in Chapel Hill, North Carolina, the US.

Cempra Inc (CEMP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Cempra Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Cempra Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Cempra Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Cempra Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Cempra Inc, Medical Devices Deals, 2012 to YTD 2018 9

Cempra Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Cempra Inc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Cempra Pharma Enters into Agreement with BARDA 11

Merger 12

Melinta Therapeutics and Cempra Merge 12

Licensing Agreements 14

Cempra Pharma Enters into Option and Licensing Agreement with Macrolide Pharma 14

Cempra Enters Into Licensing And Development Agreement With Toyama Chemical For Solithromycin 15

Cempra Enters into License Agreement with Scripps Research Institute 17

Equity Offering 18

Cempra Raises USD100 Million in Public Offering Shares 18

Cempra Raises USD148 Million in Public Offering of Shares 20

Cempra to Raise USD50 Million in Public Offering of Common Stock 22

Cempra Files Registration Statement For Public Offering Of Securities For USD 100 Million 23

Cempra Announces Private Placement Of Shares For USD 25 Million 24

Cempra Completes Public Offering Of Shares For USD 58 Million 25

Cempra Completes Private Placement Of Shares For USD 25 Million 27

Cempra Holdings Completes Exercise Of Underwriter's Option For IPO For USD 58 Million 28

Cempra Inc-Key Competitors 30

Cempra Inc-Key Employees 31

Cempra Inc-Locations And Subsidiaries 32

Head Office 32

Other Locations & Subsidiaries 32

Recent Developments 33

Financial Announcements 33

Aug 09, 2017: Cempra Provides Corporate Update and Reports Second Quarter 2017 Financial Results 33

Apr 28, 2017: Cempra Reports First Quarter 2017 Financial Results and Provides Corporate Update 35

Feb 28, 2017: Cempra Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results 37

Corporate Communications 40

Oct 31, 2017: Melinta and Cempra Name Industry Leader Daniel Wechsler as President and Chief Executive Officer of the Combined Company 40

Oct 31, 2017: Melinta and Cempra Announce Accomplished Executive Leadership Team for Combined Organization 41

Other Significant Developments 44

Nov 03, 2017: Cempra Announces Preliminary Results of 2017 Stockholder Vote 44

Appendix 45

Methodology 45

About GlobalData 45

Contact Us 45

Disclaimer 45


List Of Figure

List of Figures

Cempra Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Cempra Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Cempra Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Cempra Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Cempra Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Cempra Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Cempra Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Cempra Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Cempra Inc, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

Cempra Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2

Cempra Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Cempra Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Cempra Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Cempra Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Cempra Inc, Medical Devices Deals, 2012 to YTD 2018 9

Cempra Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Cempra Pharma Enters into Agreement with BARDA 11

Melinta Therapeutics and Cempra Merge 12

Cempra Pharma Enters into Option and Licensing Agreement with Macrolide Pharma 14

Cempra Enters Into Licensing And Development Agreement With Toyama Chemical For Solithromycin 15

Cempra Enters into License Agreement with Scripps Research Institute 17

Cempra Raises USD100 Million in Public Offering Shares 18

Cempra Raises USD148 Million in Public Offering of Shares 20

Cempra to Raise USD50 Million in Public Offering of Common Stock 22

Cempra Files Registration Statement For Public Offering Of Securities For USD 100 Million 23

Cempra Announces Private Placement Of Shares For USD 25 Million 24

Cempra Completes Public Offering Of Shares For USD 58 Million 25

Cempra Completes Private Placement Of Shares For USD 25 Million 27

Cempra Holdings Completes Exercise Of Underwriter's Option For IPO For USD 58 Million 28

Cempra Inc, Key Competitors 30

Cempra Inc, Key Employees 31

Cempra Inc, Subsidiaries 32

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Cempra Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Cempra Inc (Cempra), formerly Cempra Holdings LLC is a pharmaceutical company that develops antibacterials to the critical medical needs. The company offers products which include solithromycin and fusidic acid. It offers solithromycin, an oral and intravenous fluoroketolide. Cempra offers fusidic acid which is active against gram-positive organisms including MRSA. The company offers macrolides which are antimicrobial drugs that are active against aerobic and anaerobic gram-positive cocci and are prescribed for the treatment of respiratory tract and soft tissue infection. It markets its products across the US. Cempra is headquartered in Chapel Hill, North Carolina, the US.

Cempra Inc (CEMP)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Cempra Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Cempra Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Cempra Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Cempra Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Cempra Inc, Medical Devices Deals, 2012 to YTD 2018 9

Cempra Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Cempra Inc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Cempra Pharma Enters into Agreement with BARDA 11

Merger 12

Melinta Therapeutics and Cempra Merge 12

Licensing Agreements 14

Cempra Pharma Enters into Option and Licensing Agreement with Macrolide Pharma 14

Cempra Enters Into Licensing And Development Agreement With Toyama Chemical For Solithromycin 15

Cempra Enters into License Agreement with Scripps Research Institute 17

Equity Offering 18

Cempra Raises USD100 Million in Public Offering Shares 18

Cempra Raises USD148 Million in Public Offering of Shares 20

Cempra to Raise USD50 Million in Public Offering of Common Stock 22

Cempra Files Registration Statement For Public Offering Of Securities For USD 100 Million 23

Cempra Announces Private Placement Of Shares For USD 25 Million 24

Cempra Completes Public Offering Of Shares For USD 58 Million 25

Cempra Completes Private Placement Of Shares For USD 25 Million 27

Cempra Holdings Completes Exercise Of Underwriter's Option For IPO For USD 58 Million 28

Cempra Inc-Key Competitors 30

Cempra Inc-Key Employees 31

Cempra Inc-Locations And Subsidiaries 32

Head Office 32

Other Locations & Subsidiaries 32

Recent Developments 33

Financial Announcements 33

Aug 09, 2017: Cempra Provides Corporate Update and Reports Second Quarter 2017 Financial Results 33

Apr 28, 2017: Cempra Reports First Quarter 2017 Financial Results and Provides Corporate Update 35

Feb 28, 2017: Cempra Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results 37

Corporate Communications 40

Oct 31, 2017: Melinta and Cempra Name Industry Leader Daniel Wechsler as President and Chief Executive Officer of the Combined Company 40

Oct 31, 2017: Melinta and Cempra Announce Accomplished Executive Leadership Team for Combined Organization 41

Other Significant Developments 44

Nov 03, 2017: Cempra Announces Preliminary Results of 2017 Stockholder Vote 44

Appendix 45

Methodology 45

About GlobalData 45

Contact Us 45

Disclaimer 45


List Of Figure

List of Figures

Cempra Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Cempra Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Cempra Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Cempra Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Cempra Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Cempra Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Cempra Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Cempra Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Cempra Inc, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

Cempra Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2

Cempra Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Cempra Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Cempra Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Cempra Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Cempra Inc, Medical Devices Deals, 2012 to YTD 2018 9

Cempra Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Cempra Pharma Enters into Agreement with BARDA 11

Melinta Therapeutics and Cempra Merge 12

Cempra Pharma Enters into Option and Licensing Agreement with Macrolide Pharma 14

Cempra Enters Into Licensing And Development Agreement With Toyama Chemical For Solithromycin 15

Cempra Enters into License Agreement with Scripps Research Institute 17

Cempra Raises USD100 Million in Public Offering Shares 18

Cempra Raises USD148 Million in Public Offering of Shares 20

Cempra to Raise USD50 Million in Public Offering of Common Stock 22

Cempra Files Registration Statement For Public Offering Of Securities For USD 100 Million 23

Cempra Announces Private Placement Of Shares For USD 25 Million 24

Cempra Completes Public Offering Of Shares For USD 58 Million 25

Cempra Completes Private Placement Of Shares For USD 25 Million 27

Cempra Holdings Completes Exercise Of Underwriter's Option For IPO For USD 58 Million 28

Cempra Inc, Key Competitors 30

Cempra Inc, Key Employees 31

Cempra Inc, Subsidiaries 32

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Cempra Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.